Goldman Sachs Initiates Vaxcyte(PCVX.US) With Buy Rating, Announces Target Price $135
Goldman Sachs Initiates Coverage On Vaxcyte With Buy Rating, Announces Price Target of $135
Vaxcyte Analyst Ratings
Vaxcyte Insider Sold Shares Worth $710,249, According to a Recent SEC Filing
We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate
Vaxcyte: Promising Developments and Strategic Advancements Boost Confidence in Stock Potential
Vaxcyte Doses First Subject in Pneumococcal Conjugate Vaccine Trial in Infants
Express News | Vaxcyte Inc - on Track to Announce Vax-24 Phase 2 Infant Study Data by Q1 2025
Express News | Vaxcyte Initiates Phase 2 Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
(PCVX) - Analyzing Vaxcyte's Short Interest
Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug
Alexandria Real Estate Equities, Inc. Announces Long-Term 258,581 RSF Lease With Longstanding Tenant Vaxcyte, Inc. at the Alexandria Center for Life Science - San Carlos Mega Campus
Vaxcyte Insider Sold Shares Worth $686,518, According to a Recent SEC Filing
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
RFK and the 'MAHA Trade': Vaccine Makers Down, Psychedelic Shares up
"Anti-vaccine pioneer" nominated by Trump as Secretary of Health, vaccine stocks plummeted.
Trump nominated Robert F. Kennedy Jr. to be the Secretary of Health. Kennedy holds many unorthodox views in the field of public health, the most famous of which is questioning the safety and effectiveness of vaccines. He referred to vaccine injections as "crimes against humanity" during the COVID-19 pandemic and likened it to the Nazi Holocaust.
Vaccine-maker Stocks Like Moderna, Pfizer Drop as Trump Picks RFK Jr. to Lead HHS
Vaxcyte Gets FDA Breakthrough Therapy Designation for Its Pneumococcal Disease Treatment
Vaxcyte Announces FDA Clearance for VAX-31 Infant Phase 2 Study and Breakthrough Therapy Designation for Adult Phase 3 Study